Triple-Negative Breast Cancer (TNBC) Recruiting Phase 1 Trials for Nivolumab (DB09035)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03829436TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced CancersTreatment